Bleeding due to acquired dysfibrinogenemia as the initial presentation of multiple myeloma

Namrah Siddiq, Colin Bergstrom, Larry D. Anderson, Srikanth Nagalla

Research output: Contribution to journalArticle

Abstract

Patients with multiple myeloma (MM) are at risk for acquired dysfibrinogenemia resulting in laboratory abnormalities and/or bleeding complications. We describe a 63-year-old man who presented with bleeding diathesis in the presence of a low fibrinogen activity level with a normal fibrinogen antigen level. Further studies revealed elevated levels of lambda free light chains, and he was diagnosed with MM. Despite initiating treatment with bortezomib/dexamethasone, he continued to have recurrent bleeds along with hypofibrinogenaemia, prompting a switch to carfilzomib/dexamethasone. The patient responded with improvement in bleeding symptoms, normalisation of fibrinogen activity and a decrease in serum free light chains.

Original languageEnglish (US)
Article numbere229312
JournalBMJ Case Reports
Volume12
Issue number7
DOIs
StatePublished - Jul 1 2019

Keywords

  • cancer intervention
  • chemotherapy
  • haematology (incl blood transfusion)
  • malignant and benign haematology

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Bleeding due to acquired dysfibrinogenemia as the initial presentation of multiple myeloma'. Together they form a unique fingerprint.

  • Cite this